|
306 Companies |
|
474 Products |
|
474 Products |
|
223 Mechanisms of Action |
|
25 Trials |
|
4911 News |
|
| «12...8384858687888990919293...9899» |
- Trial completion: TACEHCC: Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (clinicaltrials.gov) - Jun 4, 2012
P4, N=164, Completed, Sponsor: Sun Yat-sen University
Active, not recruiting --> Completed
- Enrollment open: Intraoperative Dialysis in Liver Transplantation (clinicaltrials.gov) - Jun 3, 2012
P2, N=50, Recruiting, Sponsor: University of Alberta
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- New P2 trial: HEPAR-2: Radioactive Holmium Microspheres for the Treatment of Unresectable Liver Metastases (clinicaltrials.gov) - Jun 3, 2012
P2, N=48, Recruiting, Sponsor: UMC Utrecht
- pioglitazone / Generic mfg.
Trial completion: Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease (clinicaltrials.gov) - Jun 2, 2012
P2, N=184, Completed, Sponsor: Xin Gao
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- capecitabine / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Metastases: SAKK 44/02: Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Jun 1, 2012
P2, N=44, Completed, Sponsor: Swiss Group for Clinical Cancer Research
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| entecavir / Generic mfg., lamivudine / Generic mfg., adefovir dipivoxil / Generic mfg.
Enrollment change, Combination therapy, Monotherapy: DEFINE: Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus (clinicaltrials.gov) - May 31, 2012
P3, N=629, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed N=420 --> 629
- Enrollment change: Relation of Obesity With Frequency of Meals (MST 0557) (clinicaltrials.gov) - May 30, 2012
P=N/A, N=22, Completed, Sponsor: Rockefeller University
N=420 --> 629 N=50 --> 22
- ||||| ombitasvir (ABT-267) / AbbVie
New P2 trial, Combination therapy: A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study (clinicaltrials.gov) - May 30, 2012
P2, N=93, Enrolling by invitation, Sponsor: AbbVie (prior sponsor, Abbott)
- Flumadine (rimantadine) / AbbVie
Trial initiation date, Combination therapy: HepRiACT: Hepatitis C Rimantadine and Antiviral Combination Therapy (clinicaltrials.gov) - May 29, 2012
P2, N=22, Recruiting, Sponsor: The Leeds Teaching Hospitals NHS Trust
N=50 --> 22 Initiation date: Oct 2011 --> May 2012
- Flumadine (rimantadine) / AbbVie
Enrollment open, Combination therapy: HepRiACT: Hepatitis C Rimantadine and Antiviral Combination Therapy (clinicaltrials.gov) - May 29, 2012
P2, N=22, Recruiting, Sponsor: The Leeds Teaching Hospitals NHS Trust
Initiation date: Oct 2011 --> May 2012 Not yet recruiting --> Recruiting
- ||| Pegasys (pegylated interferon ? -2a) / Roche
Enrollment change, Combination therapy: STEALTHC-3: Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients (clinicaltrials.gov) - May 29, 2012
P2, N=112, Completed, Sponsor: Romark Laboratories L.C.
Not yet recruiting --> Recruiting N=90 --> 112
- faldaprevir (BI201335) / Boehringer Ingelheim
New P3 trial, Combination therapy: A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection (clinicaltrials.gov) - May 29, 2012
P3, N=0, Withdrawn, Sponsor: Boehringer Ingelheim Pharmaceuticals
- nintedanib / Generic mfg.
Enrollment open: Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma (clinicaltrials.gov) - May 29, 2012
P1, N=29, Recruiting, Sponsor: Boehringer Ingelheim
N=90 --> 112 Not yet recruiting --> Recruiting
- | tegobuvir (GS 9190) / Gilead, GS 9256 / Gilead
Trial completion, Combination therapy: Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - May 29, 2012
P2, N=46, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| Pegasys (pegylated interferon ? -2a) / Roche
Trial completion, Combination therapy: STEALTHC-3: Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients (clinicaltrials.gov) - May 29, 2012
P2, N=112, Completed, Sponsor: Romark Laboratories L.C.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Pegasys (pegylated interferon ? -2a) / Roche
Trial completion, Combination therapy: STEALTHC-2: Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C (clinicaltrials.gov) - May 29, 2012
P2, N=64, Completed, Sponsor: Romark Laboratories L.C.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Pegasys (pegylated interferon α -2a) / Roche
Enrollment open: An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (clinicaltrials.gov) - May 28, 2012
P=N/A, N=1000, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment change: PSE: Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY (clinicaltrials.gov) - May 28, 2012
P=N/A, N=50, Completed, Sponsor: University of Texas Southwestern Medical Center
Not yet recruiting --> Recruiting N=88 --> 50
- | SCY-635 / SCYNEXIS
Enrollment change, Combination therapy: Study of SCY-635, Pegasys and Copegus in Hepatitis C (clinicaltrials.gov) - May 28, 2012
P2, N=11, Completed, Sponsor: Scynexis Incorporated
N=88 --> 50 N=30 --> 11
- | INX 189 / BMS
Trial completion: Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-na (clinicaltrials.gov) - May 28, 2012
P1/2, N=50, Completed, Sponsor: Bristol-Myers Squibb
N=30 --> 11 Recruiting --> Completed
- | SCY-635 / SCYNEXIS
Trial completion, Combination therapy: Study of SCY-635, Pegasys and Copegus in Hepatitis C (clinicaltrials.gov) - May 28, 2012
P2, N=11, Completed, Sponsor: Scynexis Incorporated
Recruiting --> Completed Recruiting --> Completed
- sorafenib / Generic mfg.
Trial completion: Combination of Transcatheter Arterial Chemoembolization (TACE) and Sorafenib for Patients With Unresectable Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - May 28, 2012
P2, N=50, Completed, Sponsor: National Cancer Center, Korea
Recruiting --> Completed Recruiting --> Completed
- ||||||| Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
Trial completion, Combination therapy: VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo (clinicaltrials.gov) - May 24, 2012
P3, N=90, Completed, Sponsor: Janssen Infectious Diseases BVBA
Recruiting --> Completed Active, not recruiting --> Completed
- | New P4 trial: START 4: Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059) (clinicaltrials.gov) - May 24, 2012
P4, N=160, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | PEG Interferon / Beijing Kawin
New P1/2 trial: Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease (clinicaltrials.gov) - May 23, 2012
P1/2, N=80, Active, not recruiting, Sponsor: First Hospital of Jilin University
- | Hepabig-gene (lenvervimab) / GC Biopharma
New P1 trial: Safety and Pharmacokinetics Study of Healthy Male Adults When Repeatedly Administered Through Intravenous Injection (clinicaltrials.gov) - May 23, 2012
P1, N=36, Completed, Sponsor: Green Cross Corporation
- |||| Pegasys (pegylated interferon ? -2a) / Roche
Trial completion, Combination therapy: Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients (clinicaltrials.gov) - May 23, 2012
P2, N=147, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Pegasys (pegylated interferon ? -2a) / Roche
Trial completion, Combination therapy: Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Na (clinicaltrials.gov) - May 23, 2012
P2, N=64, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial withdrawal: Immune Response to Hepatitis C Virus (clinicaltrials.gov) - May 22, 2012
P1, N=0, Withdrawn, Sponsor: Emory University
Active, not recruiting --> Completed Recruiting --> Withdrawn
- Trial initiation date: Immune Response to Hepatitis C Virus (clinicaltrials.gov) - May 22, 2012
P1, N=0, Withdrawn, Sponsor: Emory University
Recruiting --> Withdrawn Initiation date: Jan 2005 --> Sep 2005
- Enrollment change: Immune Response to Hepatitis C Virus (clinicaltrials.gov) - May 22, 2012
P1, N=0, Withdrawn, Sponsor: Emory University
Initiation date: Jan 2005 --> Sep 2005 N=200 --> 0
- |||||||||| ribavirin / Generic mfg.
New P3 trial: Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION) (clinicaltrials.gov) - May 22, 2012
P3, N=202, Completed, Sponsor: Gilead Sciences
- sorafenib / Generic mfg.
Enrollment closed: Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant (clinicaltrials.gov) - May 22, 2012
P1, N=20, Active, not recruiting, Sponsor: University of Washington
N=200 --> 0 Completed --> Active, not recruiting
- grazoprevir (MK-5172) / Merck (MSD)
Trial withdrawal: Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022) (clinicaltrials.gov) - May 21, 2012
P1, N=0, Withdrawn, Sponsor: Merck Sharp & Dohme Corp.
Completed --> Active, not recruiting Not yet recruiting --> Withdrawn
- sorafenib / Generic mfg.
Trial termination, Metastases: Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis (clinicaltrials.gov) - May 21, 2012
P1, N=6, Terminated, Sponsor: UNC Lineberger Comprehensive Cancer Center
Not yet recruiting --> Withdrawn Completed --> Terminated; Funding unavailable
- grazoprevir (MK-5172) / Merck (MSD)
Enrollment change: Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022) (clinicaltrials.gov) - May 21, 2012
P1, N=0, Withdrawn, Sponsor: Merck Sharp & Dohme Corp.
Completed --> Terminated; Funding unavailable N=40 --> 0
- Clinical: High-protein High-fiber Diet in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - May 20, 2012
P=N/A, N=40, Recruiting, Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Trial completion: Acoustic Radiation Force Impulse-Imaging in Comparison to Transient Elastography for Liver Fibrosis Staging in HCV (clinicaltrials.gov) - May 20, 2012
P=N/A, N=0, Completed, Sponsor: Johann Wolfgang Goethe University Hospitals
N=40 --> 0 Recruiting --> Completed
- Pegasys (pegylated interferon ? -2a) / Roche
Enrollment change, Combination therapy: A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy (clinicaltrials.gov) - May 20, 2012
P1, N=31, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed N=17 --> 31
- TB-403 / Oxurion
Enrollment change, Combination therapy, Metastases: A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma (clinicaltrials.gov) - May 20, 2012
P1, N=6, Completed, Sponsor: Hoffmann-La Roche
N=17 --> 31 N=60 --> 6
- | Pegasys (pegylated interferon ? -2a) / Roche
Trial completion, Combination therapy: A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy (clinicaltrials.gov) - May 20, 2012
P1, N=31, Completed, Sponsor: Hoffmann-La Roche
N=60 --> 6 Active, not recruiting --> Completed
- TB-403 / Oxurion
Trial completion, Combination therapy, Metastases: A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma (clinicaltrials.gov) - May 20, 2012
P1, N=6, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Completed
- Enrollment change: Cerebrovascular Reactivity in Hepatic Encephalopathy (clinicaltrials.gov) - May 16, 2012
P=N/A, N=90, Completed, Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Recruiting --> Completed N=60 --> 90
- Trial completion: Cerebrovascular Reactivity in Hepatic Encephalopathy (clinicaltrials.gov) - May 16, 2012
P=N/A, N=90, Completed, Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
N=60 --> 90 Recruiting --> Completed
- ||| Arlansa (narlaprevir) / Merck (MSD)
Enrollment change: NEXT-1: A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED) (clinicaltrials.gov) - May 15, 2012
P2, N=111, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed N=140 --> 111
- ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Enrollment change: HEPCPR: Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients (clinicaltrials.gov) - May 15, 2012
P2, N=40, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=140 --> 111 N=180 --> 40
- | Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
New P1 trial: A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment (clinicaltrials.gov) - May 15, 2012
P1, N=24, Completed, Sponsor: Janssen Infectious Diseases BVBA
- grazoprevir (MK-5172) / Merck (MSD)
Trial termination: Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012) (clinicaltrials.gov) - May 14, 2012
P2, N=5, Terminated, Sponsor: Merck
N=180 --> 40 Active, not recruiting --> Terminated; Preliminary results of MK-5172 PN003 (NCT01353911) suggested a possible dose relationship to elevated transaminase levels in treatment with grazoprevir.
- grazoprevir (MK-5172) / Merck (MSD)
Enrollment change: Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012) (clinicaltrials.gov) - May 14, 2012
P2, N=5, Terminated, Sponsor: Merck
Active, not recruiting --> Terminated; Preliminary results of MK-5172 PN003 (NCT01353911) suggested a possible dose relationship to elevated transaminase levels in treatment with grazoprevir. N=120 --> 5
- odanacatib (MK-0822) / Merck (MSD)
Trial completion: Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insufficiency (MK-0822-070) (clinicaltrials.gov) - May 14, 2012
P1, N=16, Completed, Sponsor: Merck
N=120 --> 5 Active, not recruiting --> Completed